James Lapworth joins NanoSyrinx as Chief Business Officer

Dr James Lapworth has joined the NanoSyrinx management team as Chief Business Officer to support the company in delivering its ambitious plans following the recent announcement of our oversubscribed Seed+ funding round.


James is an experienced business development and technology commercialisation professional with over 10 years’ experience in fundraising, developing, partnering and out-licensing new technologies, particularly in the drug discovery, biotech and med-tech sectors. In his previous role at Warwick Ventures he identified and managed a portfolio of >60 new inventions leading to 6 new spinout companies which raised a total of £10m in seed stage equity financing between 2018-2021. During this time, he also sat on the management committees of the Warwick Integrative Synthetic Biology Centre and the Warwick-Wellcome Translational Partnership.


In earlier roles, he established multiple early-stage discovery partnerships, including supporting Prof Simon Wagner to secure one of Europe’s first GSK Discovery Fast Track Challenge awards, leading to a collaborative partnership with GSK aimed at discovering new medicines for the treatment of non-Hodgkin’s lymphoma.


Joe Healey, CEO, said:

“James has been intimately involved in the establishment of NanoSyrinx over the past 5 years and I am delighted that we have been able to bring him onboard full time to support the company’s growth.”


James holds a First Class dual honours degree in Biology & Chemistry and a PhD in Synthetic Chemistry and Regenerative Medicine from the University of Sheffield. He is a Member of the Royal Society of Chemistry, a Chartered Chemist and a Registered PRINCE2 practitioner.

Read more news

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – https://www.scienceinparliament.org.uk/) to discuss the future and potential of Synthetic Biology for the UK and for human health. The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. […]

Read more

NanoSyrinx featured by Spin-up Science on YouTube

Ben Miles at Spin-up Science took time recently to feature NanoSyrinx in their latest YouTube video. Follow the links below to learn how what NanoSyrinx is developing could, in Ben’s words, “change medicine forever”. You can also hear more from the discussion on the Scientist-to-CEO podcast Ben runs, which is available here: Spin up Science […]

Read more

NanoSyrinx named as winner of the 2022 AbbVie UK Golden Ticket programme

NanoSyrinx has been named as the winner of the 2022 AbbVie UK Golden Ticket accelerator programme. The 2022 AbbVie UK Golden Ticket is a competitive award, open to early-stage life sciences companies and biotech start-ups that are working to develop cutting-edge therapies or technology platforms. Under the programme, the company will benefit from: One year […]

Read more